Immunoglobulin replacement therapy has been used for decades and continues to be the core treatment modality for patients with XLA. Although there are isolated reports of successful immune reconstitution using stem cell transplants from HLA-identical donors as well as attempts at gene replacement therapy, these approaches are not currently standard of care due to risks outweighing benefits.